VVESF logo

Vivesto AB

VVESF

$0.07

Key details

CEO

Francois Martelet

Employees

28

Headquarters

Uppsala, Sweden

Sector

Manufacturing

Industry

Pharmaceutical Preparation Manufacturing

About Vivesto AB

oasmia pharmaceutical ab develops a new generation of drugs within human and veterinary oncology. the product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. the product development is based on in-house research within nanotechnology and company patents.

Please treat this data as an indicator only since we can't always guarantee that it's accurate or complete. Bear in mind too that the prices you'll see are delayed by at least 15 minutes. Intraday pricing and company data provided by IEX.
Finimize
© Finimize Ltd. 2023. 10328011. 280 Bishopsgate, London, EC2M 4AG